1. Home
  2. SOPH vs MGTX Comparison

SOPH vs MGTX Comparison

Compare SOPH & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SOPHiA GENETICS SA

SOPH

SOPHiA GENETICS SA

N/A

Current Price

$7.40

Market Cap

462.3M

Sector

Health Care

ML Signal

N/A

Logo MeiraGTx Holdings plc

MGTX

MeiraGTx Holdings plc

N/A

Current Price

$10.70

Market Cap

1.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SOPH
MGTX
Founded
2011
2015
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
462.3M
1.0B
IPO Year
2021
2018

Fundamental Metrics

Financial Performance
Metric
SOPH
MGTX
Price
$7.40
$10.70
Analyst Decision
Strong Buy
Buy
Analyst Count
5
8
Target Price
$9.75
★ $27.75
AVG Volume (30 Days)
651.2K
★ 1.0M
Earning Date
11-03-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 33.02
EPS
N/A
★ 1.30
Revenue
N/A
★ $81,391,000.00
Revenue This Year
$23.24
$314.19
Revenue Next Year
$24.63
N/A
P/E Ratio
★ N/A
$8.08
Revenue Growth
N/A
★ 144.57
52 Week Low
$3.75
$6.62
52 Week High
$8.98
$15.35

Technical Indicators

Market Signals
Indicator
SOPH
MGTX
Relative Strength Index (RSI) 41.46 33.38
Support Level $4.58 $8.84
Resistance Level $8.80 $10.71
Average True Range (ATR) 0.48 0.58
MACD -0.14 -0.05
Stochastic Oscillator 29.60 12.33

Price Performance

Historical Comparison
SOPH
MGTX

About SOPH SOPHiA GENETICS SA

Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.

About MGTX MeiraGTx Holdings plc

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.

Share on Social Networks: